Upadacitinib is a Jak1 inhibitor, which has shown good efficacy in clinical trials for the treatment of a variety of autoimmune and inflammatory diseases.
Synonymous | (3S, 4R) - 3-ethyl-4 - (3h-imidazo [1,2-a] pyrrolo [2,3-e] pyrazine-8-yl) - N - (2,2,2-trifluoroethyl) pyrrolidine-1-amide |
Structure | |
CAS | 1310726-60-3 |
Molecular Formula | C17H19F3N6O |
Molecular Weight | 380.37 |
Appearance | White powder |
Packing | 25kg cardboard barrel |
Uses | Treat a variety of autoimmune and inflammatory diseases |
Storage | Dark and dry |
Upatinib is an oral Jak1 inhibitor used to treat rheumatoid arthritis, psoriatic arthritis and other diseases. JAK kinase, a family of non receptor tyrosine kinases, has found four members, namely Jak1, JAK2, JAK3 and TYK1.